Difference between revisions of "Telotristat (Xermelo)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tryptophan hydroxylase inhibitor. Tryptophan hydroxylase controls the rate limiting step of the biosynthesis of serotonin, which plays a role in regulating the secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Telotristat reduces the frequency of carcinoid syndrome diarrhea by decreasing the production of serotonin.<ref name="insert">[http://xermelo.com/Media/Default/pdfs/Product_Info_telotristat_etiprate.pdf Telotristat (Xermelo) package insert]</ref><ref>[[File:Telotristat.pdf | Telotristat (Xermelo) package insert (locally hosted backup)]]</ref><ref>[http://xermelo.com/ Xermelo manufacturer's website]</ref> | + | Class/mechanism: Tryptophan hydroxylase inhibitor. Tryptophan hydroxylase controls the rate limiting step of the biosynthesis of serotonin, which plays a role in regulating the secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Telotristat reduces the frequency of carcinoid syndrome diarrhea by decreasing the production of serotonin.<ref name="insert">[http://xermelo.com/Media/Default/pdfs/Product_Info_telotristat_etiprate.pdf Telotristat (Xermelo) package insert]</ref><ref>[[:File:Telotristat.pdf | Telotristat (Xermelo) package insert (locally hosted backup)]]</ref><ref>[http://xermelo.com/ Xermelo manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. |
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 13: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2017-02-28: [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544035.htm Initial FDA approval] to be used in combination with [[:Category:Somatostatin analogs|somatostatin analog (SSA) therapy]] for the treatment of adults with [[Neuroendocrine tumor|carcinoid]] syndrome diarrhea that SSA therapy alone has inadequately controlled. |
| + | |||
| + | ==History of changes in EMA ndication== | ||
| + | *2017-09-17: Initial authorization | ||
==Also known as== | ==Also known as== | ||
| Line 26: | Line 26: | ||
[[Category:Tryptophan hydroxylase inhibitors]] | [[Category:Tryptophan hydroxylase inhibitors]] | ||
| − | [[Category: | + | [[Category:EMA approved in 2017]] |
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
Latest revision as of 00:10, 6 July 2024
General information
Class/mechanism: Tryptophan hydroxylase inhibitor. Tryptophan hydroxylase controls the rate limiting step of the biosynthesis of serotonin, which plays a role in regulating the secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Telotristat reduces the frequency of carcinoid syndrome diarrhea by decreasing the production of serotonin.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
Patient drug information
- Brief patient counseling information can be found in the Telotristat (Xermelo) package insert[1]
History of changes in FDA indication
- 2017-02-28: Initial FDA approval to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled.
History of changes in EMA ndication
- 2017-09-17: Initial authorization
Also known as
- Generic name: telotristat ethyl as telotristat etiprate
- Brand name: Xermelo